Identification

Name
Galantamine
Accession Number
DB00674  (APRD00206, EXPT01628)
Type
Small Molecule
Groups
Approved
Description

A benzazepine derived from norbelladine. It is found in galanthus and other amaryllidaceae. Galantamine is a cholinesterase inhibitor that has been used to reverse the muscular effects of gallamine triethiodide and tubocurarine, and has been studied as a treatment for Alzheimer's disease and other central nervous system disorders.

Structure
Thumb
Synonyms
  • (-)-Galanthamine
  • Galanthamine
External IDs
NSC-100058
Product Ingredients
IngredientUNIICASInChI Key
Galantamine hydrobromideMJ4PTD2VVW1953-04-4QORVDGQLPPAFRS-XPSHAMGMSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Auro-galantamine ERCapsule, extended release16 mgOralAuro Pharma Inc2014-06-12Not applicableCanada
Auro-galantamine ERCapsule, extended release24 mgOralAuro Pharma Inc2014-06-12Not applicableCanada
Auro-galantamine ERCapsule, extended release8 mgOralAuro Pharma Inc2014-06-12Not applicableCanada
Galantamine ERCapsule, extended release24 mgOralSanis Health Inc2016-01-11Not applicableCanada
Galantamine ERCapsule, extended release8 mgOralPro Doc Limitee2013-12-03Not applicableCanada
Galantamine ERCapsule, extended release16 mgOralSanis Health Inc2016-01-11Not applicableCanada
Galantamine ERCapsule, extended release16 mgOralPro Doc Limitee2013-12-03Not applicableCanada
Galantamine ERCapsule, extended release8 mgOralSanis Health Inc2016-01-11Not applicableCanada
Galantamine ERCapsule, extended release24 mgOralPro Doc Limitee2013-12-03Not applicableCanada
Galantamine HydrobromideTablet, film coated8 mg/1OralPatriot Pharmaceuticals2001-02-28Not applicableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-galantamineTablet4 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-galantamineTablet8 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-galantamineTablet12 mgOralApotex CorporationNot applicableNot applicableCanada
GalantamineTablet, film coated4 mg/1OralTeva2008-08-282018-01-31Us00555 0138 09 nlmimage10 122b894c
GalantamineTablet4 mg/1OralWest Ward Pharmaceutical2016-06-01Not applicableUs
GalantamineTablet, film coated8 mg/1OralCitron Pharma LLC2011-03-29Not applicableUs
GalantamineTablet, film coated4 mg/1OralAurobindo Pharma2011-03-29Not applicableUs
GalantamineTablet, film coated4 mg/1OralAmerincan Health Packaging2014-06-01Not applicableUs
GalantamineCapsule, extended release16 mg/1OralTeva2008-10-152018-05-31Us00555 1021 01 nlmimage10 d52b6aeb
GalantamineTablet, film coated12 mg/1OralMylan Institutional2009-11-092017-11-01Us
International/Other Brands
Lycoremine / Nivalin / Reminyl
Categories
UNII
0D3Q044KCA
CAS number
357-70-0
Weight
Average: 287.3535
Monoisotopic: 287.152143543
Chemical Formula
C17H21NO3
InChI Key
ASUTZQLVASHGKV-JDFRZJQESA-N
InChI
InChI=1S/C17H21NO3/c1-18-8-7-17-6-5-12(19)9-14(17)21-16-13(20-2)4-3-11(10-18)15(16)17/h3-6,12,14,19H,7-10H2,1-2H3/t12-,14-,17-/m0/s1
IUPAC Name
(1S,12S,14R)-9-methoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6(17),7,9,15-tetraen-14-ol
SMILES
[H][[email protected]]12C[[email protected]@H](O)C=C[[email protected]]11CCN(C)CC3=C1C(O2)=C(OC)C=C3

Pharmacology

Indication

For the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease.

Structured Indications
Pharmacodynamics

Galantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. It is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. An early pathophysiological feature of Alzheimer's disease that is associated with memory loss and cognitive deficits is a deficiency of acetylcholine as a result of selective loss of cholinergic neurons in the cerebral cortex, nucleus basalis, and hippocampus. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine's effect may lessen as the disease progresses and fewer cholinergic neurons remain functionally intact. There is no evidence that Galantamine alters the course of the underlying dementing process.

Mechanism of action

Galantamine is a phenanthrene alkaloid and a reversible, competitive acetylcholinesterase inhibitor. It is not structurally related to other acetylcholinesterase inhibitors. Galantamine's proposed mechanism of action involves the reversible inhibition of acetylcholinesterase, which prevents the hydrolysis of acetycholine, leading to an increased concentration of acetylcholine at cholinergic synapses. Galantamine also binds allosterically with nicotinic acetylcholine receptors and may possibly potentiate the action of agonists (such as acetylcholine) at these receptors.

TargetActionsOrganism
AAcetylcholinesterase
inhibitor
Human
UAcetylcholine receptor subunit alpha
allosteric modulator
Human
UAcetylcholine receptor subunit beta
allosteric modulator
Human
UAcetylcholine receptor subunit delta
allosteric modulator
Human
UAcetylcholine receptor subunit gamma
allosteric modulator
Human
UAcetylcholine receptor subunit epsilon
allosteric modulator
Human
UNeuronal acetylcholine receptor subunit alpha-2
allosteric modulator
Human
UNeuronal acetylcholine receptor subunit alpha-3
allosteric modulator
Human
UNeuronal acetylcholine receptor subunit alpha-4
allosteric modulator
Human
UNeuronal acetylcholine receptor subunit alpha-5
allosteric modulator
Human
UNeuronal acetylcholine receptor subunit alpha-6
allosteric modulator
Human
UNeuronal acetylcholine receptor subunit alpha-7
allosteric modulator
Human
UNeuronal acetylcholine receptor subunit alpha-9
allosteric modulator
Human
UNeuronal acetylcholine receptor subunit alpha-10
allosteric modulator
Human
UNeuronal acetylcholine receptor subunit beta-2
allosteric modulator
Human
UNeuronal acetylcholine receptor subunit beta-3
allosteric modulator
Human
UNeuronal acetylcholine receptor subunit beta-4
allosteric modulator
Human
UCholinesterase
inhibitor
Human
Absorption
Not Available
Volume of distribution
  • 175 L
Protein binding

18%

Metabolism
Route of elimination

Galantamine is metabolized by hepatic cytochrome P450 enzymes, glucuronidated, and excreted unchanged in the urine.

Half life

7 hours

Clearance
  • 300 mL/min [After IV. or oral administration]
Toxicity

LD50=75 mg/kg (rat)

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*4Not AvailableC alleleEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCEffect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all Effect InferredPoor drug metabolizer.Details
Cytochrome P450 3A4CYP3A4*20Not Available1461_1462insAEffect InferredPoor drug metabolizer.Details
Cytochrome P450 3A4CYP3A4*26Not Available802C>TEffect InferredPoor drug metabolizer.Details

Interactions

Drug Interactions
DrugInteractionDrug group
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when 16-Bromoepiandrosterone is combined with Galantamine.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when 19-norandrostenedione is combined with Galantamine.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when 5-androstenedione is combined with Galantamine.Experimental, Illicit
AbirateroneThe serum concentration of Galantamine can be increased when it is combined with Abiraterone.Approved
AcebutololGalantamine may increase the bradycardic activities of Acebutolol.Approved
AcetylcholineThe risk or severity of adverse effects can be increased when Galantamine is combined with Acetylcholine.Approved
AclidiniumThe therapeutic efficacy of Aclidinium can be decreased when used in combination with Galantamine.Approved
AlaproclateThe metabolism of Galantamine can be decreased when combined with Alaproclate.Experimental
AlclometasoneThe risk or severity of adverse effects can be increased when Alclometasone is combined with Galantamine.Approved
AlcuroniumThe therapeutic efficacy of Alcuronium can be decreased when used in combination with Galantamine.Experimental
AldosteroneThe risk or severity of adverse effects can be increased when Aldosterone is combined with Galantamine.Experimental, Investigational
AlprenololGalantamine may increase the bradycardic activities of Alprenolol.Approved, Withdrawn
AmcinonideThe risk or severity of adverse effects can be increased when Amcinonide is combined with Galantamine.Approved
AmiodaroneThe metabolism of Galantamine can be decreased when combined with Amiodarone.Approved, Investigational
AnagrelideGalantamine may increase the QTc-prolonging activities of Anagrelide.Approved
AndrostenedioneThe risk or severity of adverse effects can be increased when Androstenedione is combined with Galantamine.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Anecortave is combined with Galantamine.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when anecortave acetate is combined with Galantamine.Investigational
Anisotropine MethylbromideThe therapeutic efficacy of Anisotropine Methylbromide can be decreased when used in combination with Galantamine.Approved
AprepitantThe serum concentration of Galantamine can be increased when it is combined with Aprepitant.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Galantamine is combined with Arecoline.Experimental
ArotinololGalantamine may increase the bradycardic activities of Arotinolol.Approved, Investigational
Arsenic trioxideGalantamine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherGalantamine may increase the QTc-prolonging activities of Artemether.Approved
AsenapineGalantamine may increase the QTc-prolonging activities of Asenapine.Approved
AtamestaneThe risk or severity of adverse effects can be increased when Atamestane is combined with Galantamine.Investigational
AtazanavirThe metabolism of Galantamine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololGalantamine may increase the bradycardic activities of Atenolol.Approved
AtomoxetineThe metabolism of Galantamine can be decreased when combined with Atomoxetine.Approved
AtracuriumThe therapeutic efficacy of Atracurium can be decreased when used in combination with Galantamine.Experimental, Investigational
Atracurium besylateThe therapeutic efficacy of Atracurium besylate can be decreased when used in combination with Galantamine.Approved
AtropineThe therapeutic efficacy of Atropine can be decreased when used in combination with Galantamine.Approved, Vet Approved
AzithromycinGalantamine may increase the QTc-prolonging activities of Azithromycin.Approved
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Galantamine.Approved, Investigational
BedaquilineGalantamine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololGalantamine may increase the bradycardic activities of Befunolol.Experimental
BenactyzineThe therapeutic efficacy of Benactyzine can be decreased when used in combination with Galantamine.Withdrawn
BendroflumethiazideBendroflumethiazide may increase the bradycardic activities of Galantamine.Approved
BenzatropineThe therapeutic efficacy of Benzatropine can be decreased when used in combination with Galantamine.Approved
BeractantGalantamine may increase the bradycardic activities of Beractant.Approved
BetamethasoneThe risk or severity of adverse effects can be increased when Betamethasone is combined with Galantamine.Approved, Vet Approved
BetaxololGalantamine may increase the bradycardic activities of Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Galantamine is combined with Bethanechol.Approved
BevantololGalantamine may increase the bradycardic activities of Bevantolol.Approved
BiperidenThe therapeutic efficacy of Biperiden can be decreased when used in combination with Galantamine.Approved, Investigational
BisoprololGalantamine may increase the bradycardic activities of Bisoprolol.Approved
BoceprevirThe metabolism of Galantamine can be decreased when combined with Boceprevir.Approved, Withdrawn
BopindololGalantamine may increase the bradycardic activities of Bopindolol.Approved
BornaprineThe therapeutic efficacy of Bornaprine can be decreased when used in combination with Galantamine.Experimental
BortezomibThe metabolism of Galantamine can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Galantamine can be decreased when it is combined with Bosentan.Approved, Investigational
BretyliumBretylium may increase the bradycardic activities of Galantamine.Approved
BucindololGalantamine may increase the bradycardic activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Budesonide is combined with Galantamine.Approved
BufuralolGalantamine may increase the bradycardic activities of Bufuralol.Experimental, Investigational
BupranololGalantamine may increase the bradycardic activities of Bupranolol.Approved
BupropionThe metabolism of Galantamine can be decreased when combined with Bupropion.Approved
CalfactantGalantamine may increase the bradycardic activities of Calfactant.Approved
CarbacholThe risk or severity of adverse effects can be increased when Galantamine is combined with Carbachol.Approved
CarbamazepineThe metabolism of Galantamine can be increased when combined with Carbamazepine.Approved, Investigational
CarteololGalantamine may increase the bradycardic activities of Carteolol.Approved
CarvedilolGalantamine may increase the bradycardic activities of Carvedilol.Approved, Investigational
CelecoxibThe metabolism of Galantamine can be decreased when combined with Celecoxib.Approved, Investigational
CeliprololGalantamine may increase the bradycardic activities of Celiprolol.Approved, Investigational
CeritinibThe serum concentration of Galantamine can be increased when it is combined with Ceritinib.Approved
CevimelineThe risk or severity of adverse effects can be increased when Galantamine is combined with Cevimeline.Approved
ChloroquineGalantamine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenoxamineThe therapeutic efficacy of Chlorphenoxamine can be decreased when used in combination with Galantamine.Withdrawn
ChlorpromazineGalantamine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
CholecalciferolThe metabolism of Galantamine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CiclesonideThe risk or severity of adverse effects can be increased when Ciclesonide is combined with Galantamine.Approved, Investigational
CimetidineThe metabolism of Galantamine can be decreased when combined with Cimetidine.Approved
CinacalcetThe metabolism of Galantamine can be decreased when combined with Cinacalcet.Approved
CiprofloxacinGalantamine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisaprideGalantamine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramThe metabolism of Galantamine can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Galantamine can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Galantamine can be decreased when combined with Clemastine.Approved
ClobazamThe metabolism of Galantamine can be decreased when combined with Clobazam.Approved, Illicit
ClobetasolThe risk or severity of adverse effects can be increased when Clobetasol is combined with Galantamine.Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Clobetasol propionate is combined with Galantamine.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Clobetasone is combined with Galantamine.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Clocortolone is combined with Galantamine.Approved
ClomipramineThe metabolism of Galantamine can be decreased when combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the bradycardic activities of Galantamine.Approved
CloranololGalantamine may increase the bradycardic activities of Cloranolol.Experimental
ClotrimazoleThe metabolism of Galantamine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineGalantamine may increase the QTc-prolonging activities of Clozapine.Approved
CobicistatThe serum concentration of Galantamine can be increased when it is combined with Cobicistat.Approved
CocaineThe metabolism of Galantamine can be decreased when combined with Cocaine.Approved, Illicit
ConivaptanThe serum concentration of Galantamine can be increased when it is combined with Conivaptan.Approved, Investigational
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Cortexolone 17α-propionate is combined with Galantamine.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Corticosterone is combined with Galantamine.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Cortisone acetate is combined with Galantamine.Approved
CrizotinibGalantamine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclopentolateThe therapeutic efficacy of Cyclopentolate can be decreased when used in combination with Galantamine.Approved
CyclosporineThe metabolism of Galantamine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
DabrafenibThe serum concentration of Galantamine can be decreased when it is combined with Dabrafenib.Approved
DapoxetineThe metabolism of Galantamine can be decreased when combined with Dapoxetine.Investigational
DarifenacinThe therapeutic efficacy of Darifenacin can be decreased when used in combination with Galantamine.Approved, Investigational
DarunavirThe serum concentration of Galantamine can be increased when it is combined with Darunavir.Approved
DasatinibThe serum concentration of Galantamine can be increased when it is combined with Dasatinib.Approved, Investigational
DeferasiroxThe serum concentration of Galantamine can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Galantamine can be decreased when combined with Delavirdine.Approved
DesipramineThe metabolism of Galantamine can be decreased when combined with Desipramine.Approved
DesloratadineThe therapeutic efficacy of Desloratadine can be decreased when used in combination with Galantamine.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Desoximetasone is combined with Galantamine.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Desoxycorticosterone acetate is combined with Galantamine.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Desoxycorticosterone Pivalate is combined with Galantamine.Experimental, Vet Approved
DesvenlafaxineThe metabolism of Galantamine can be decreased when combined with Desvenlafaxine.Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Dexamethasone is combined with Galantamine.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Dexamethasone isonicotinate is combined with Galantamine.Vet Approved
DexetimideThe therapeutic efficacy of Dexetimide can be decreased when used in combination with Galantamine.Withdrawn
DexmedetomidineDexmedetomidine may increase the bradycardic activities of Galantamine.Approved, Vet Approved
DicyclomineThe therapeutic efficacy of Dicyclomine can be decreased when used in combination with Galantamine.Approved
DiflorasoneThe risk or severity of adverse effects can be increased when Diflorasone is combined with Galantamine.Approved
DifluocortoloneThe risk or severity of adverse effects can be increased when Difluocortolone is combined with Galantamine.Approved, Investigational
DifluprednateThe risk or severity of adverse effects can be increased when Difluprednate is combined with Galantamine.Approved
DigoxinDigoxin may increase the bradycardic activities of Galantamine.Approved
DihydroergotamineThe metabolism of Galantamine can be decreased when combined with Dihydroergotamine.Approved
DiltiazemThe metabolism of Galantamine can be decreased when combined with Diltiazem.Approved
DiphenhydramineThe metabolism of Galantamine can be decreased when combined with Diphenhydramine.Approved
DipyridamoleThe therapeutic efficacy of Galantamine can be decreased when used in combination with Dipyridamole.Approved
DisopyramideGalantamine may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilideGalantamine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronGalantamine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidoneGalantamine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilGalantamine may increase the bradycardic activities of Donepezil.Approved
DosulepinThe metabolism of Galantamine can be decreased when combined with Dosulepin.Approved
DoxycyclineThe metabolism of Galantamine can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneGalantamine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolGalantamine may increase the QTc-prolonging activities of Droperidol.Approved, Vet Approved
DuloxetineThe metabolism of Galantamine can be decreased when combined with Duloxetine.Approved
EliglustatGalantamine may increase the QTc-prolonging activities of Eliglustat.Approved
EmeproniumThe therapeutic efficacy of Emepronium can be decreased when used in combination with Galantamine.Experimental
EnzalutamideThe serum concentration of Galantamine can be decreased when it is combined with Enzalutamide.Approved
EpanololGalantamine may increase the bradycardic activities of Epanolol.Experimental
EpibatidineThe risk or severity of adverse effects can be increased when Galantamine is combined with Epibatidine.Experimental
EquileninThe risk or severity of adverse effects can be increased when Equilenin is combined with Galantamine.Experimental
EquilinThe risk or severity of adverse effects can be increased when Equilin is combined with Galantamine.Approved
ErythromycinGalantamine may increase the QTc-prolonging activities of Erythromycin.Approved, Vet Approved
EscitalopramThe metabolism of Galantamine can be decreased when combined with Escitalopram.Approved, Investigational
EsmololGalantamine may increase the bradycardic activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Estrone is combined with Galantamine.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Galantamine.Approved
EtanautineThe therapeutic efficacy of Etanautine can be decreased when used in combination with Galantamine.Experimental
EthopropazineThe therapeutic efficacy of Ethopropazine can be decreased when used in combination with Galantamine.Approved
EtoperidoneThe metabolism of Galantamine can be decreased when combined with Etoperidone.Withdrawn
EtybenzatropineThe therapeutic efficacy of Etybenzatropine can be decreased when used in combination with Galantamine.Experimental
FesoterodineThe therapeutic efficacy of Fesoterodine can be decreased when used in combination with Galantamine.Approved
FingolimodGalantamine may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlecainideGalantamine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
fluasteroneThe risk or severity of adverse effects can be increased when fluasterone is combined with Galantamine.Investigational
FluconazoleThe metabolism of Galantamine can be decreased when combined with Fluconazole.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Fludrocortisone is combined with Galantamine.Approved
FlumethasoneThe risk or severity of adverse effects can be increased when Flumethasone is combined with Galantamine.Approved, Vet Approved
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Fluocinolone Acetonide is combined with Galantamine.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Fluocinonide is combined with Galantamine.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Fluocortolone is combined with Galantamine.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Fluorometholone is combined with Galantamine.Approved
FluoxetineThe metabolism of Galantamine can be decreased when combined with Fluoxetine.Approved, Vet Approved
FlupentixolGalantamine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluprednideneThe risk or severity of adverse effects can be increased when Fluprednidene is combined with Galantamine.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Fluprednisolone is combined with Galantamine.Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Flurandrenolide is combined with Galantamine.Approved
FluvoxamineThe metabolism of Galantamine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormestaneThe risk or severity of adverse effects can be increased when Formestane is combined with Galantamine.Approved, Investigational, Withdrawn
FosamprenavirThe metabolism of Galantamine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Galantamine can be increased when it is combined with Fosaprepitant.Approved
FosphenytoinThe metabolism of Galantamine can be increased when combined with Fosphenytoin.Approved
Fusidic AcidThe serum concentration of Galantamine can be increased when it is combined with Fusidic Acid.Approved
Gadobenic acidGalantamine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GallamineThe therapeutic efficacy of Gallamine can be decreased when used in combination with Galantamine.Experimental
Gallamine TriethiodideThe therapeutic efficacy of Gallamine Triethiodide can be decreased when used in combination with Galantamine.Approved
GemifloxacinGalantamine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GlycopyrroniumThe therapeutic efficacy of Glycopyrronium can be decreased when used in combination with Galantamine.Approved, Investigational, Vet Approved
GoserelinGalantamine may increase the QTc-prolonging activities of Goserelin.Approved
GranisetronGalantamine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GTS-21The risk or severity of adverse effects can be increased when Galantamine is combined with GTS-21.Investigational
GuanfacineGalantamine may increase the bradycardic activities of Guanfacine.Approved, Investigational
HaloperidolGalantamine may increase the QTc-prolonging activities of Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when HE3286 is combined with Galantamine.Investigational
HexamethoniumThe therapeutic efficacy of Hexamethonium can be decreased when used in combination with Galantamine.Experimental
HomatropineThe therapeutic efficacy of Homatropine can be decreased when used in combination with Galantamine.Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Hydrocortisone is combined with Galantamine.Approved, Vet Approved
HyoscyamineThe therapeutic efficacy of Hyoscyamine can be decreased when used in combination with Galantamine.Approved
IbutilideGalantamine may increase the QTc-prolonging activities of Ibutilide.Approved
IdelalisibThe serum concentration of Galantamine can be increased when it is combined with Idelalisib.Approved
IloperidoneGalantamine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Galantamine can be decreased when combined with Imatinib.Approved
ImipramineThe metabolism of Galantamine can be decreased when combined with Imipramine.Approved
IndalpineThe metabolism of Galantamine can be decreased when combined with Indalpine.Investigational, Withdrawn
IndenololGalantamine may increase the bradycardic activities of Indenolol.Withdrawn
IndinavirThe metabolism of Galantamine can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe therapeutic efficacy of Ipratropium bromide can be decreased when used in combination with Galantamine.Approved
IsavuconazoniumThe metabolism of Galantamine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoniazidThe metabolism of Galantamine can be decreased when combined with Isoniazid.Approved
IsradipineThe metabolism of Galantamine can be decreased when combined with Isradipine.Approved
IstaroximeThe risk or severity of adverse effects can be increased when Istaroxime is combined with Galantamine.Investigational
ItraconazoleThe metabolism of Galantamine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineGalantamine may increase the bradycardic activities of Ivabradine.Approved
IvacaftorThe serum concentration of Galantamine can be increased when it is combined with Ivacaftor.Approved
KetoconazoleThe metabolism of Galantamine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolGalantamine may increase the bradycardic activities of Labetalol.Approved
LacosamideGalantamine may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
LandiololGalantamine may increase the bradycardic activities of Landiolol.Investigational
LanreotideGalantamine may increase the bradycardic activities of Lanreotide.Approved
LenvatinibGalantamine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideGalantamine may increase the QTc-prolonging activities of Leuprolide.Approved, Investigational
LevobunololGalantamine may increase the bradycardic activities of Levobunolol.Approved
LevofloxacinGalantamine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
LevomilnacipranThe metabolism of Galantamine can be decreased when combined with Levomilnacipran.Approved
LobelineThe risk or severity of adverse effects can be increased when Galantamine is combined with Lobeline.Investigational
LopinavirThe metabolism of Galantamine can be decreased when combined with Lopinavir.Approved
LorcaserinThe metabolism of Galantamine can be decreased when combined with Lorcaserin.Approved
LovastatinThe metabolism of Galantamine can be decreased when combined with Lovastatin.Approved, Investigational
LucinactantGalantamine may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Galantamine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe metabolism of Galantamine can be increased when combined with Lumacaftor.Approved
LumefantrineGalantamine may increase the QTc-prolonging activities of Lumefantrine.Approved
ManidipineThe metabolism of Galantamine can be decreased when combined with Manidipine.Approved, Investigational
MazaticolThe therapeutic efficacy of Mazaticol can be decreased when used in combination with Galantamine.Experimental
ME-609The risk or severity of adverse effects can be increased when ME-609 is combined with Galantamine.Investigational
MecamylamineThe therapeutic efficacy of Mecamylamine can be decreased when used in combination with Galantamine.Approved
MedrysoneThe risk or severity of adverse effects can be increased when Medrysone is combined with Galantamine.Approved
MelengestrolThe risk or severity of adverse effects can be increased when Melengestrol is combined with Galantamine.Vet Approved
MepindololGalantamine may increase the bradycardic activities of Mepindolol.Experimental
MethacholineThe risk or severity of adverse effects can be increased when Galantamine is combined with Methacholine.Approved
MethadoneGalantamine may increase the QTc-prolonging activities of Methadone.Approved
MethanthelineThe therapeutic efficacy of Methantheline can be decreased when used in combination with Galantamine.Approved, Investigational
MethotrimeprazineThe metabolism of Galantamine can be decreased when combined with Methotrimeprazine.Approved
MethyldopaGalantamine may increase the bradycardic activities of Methyldopa.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Methylprednisolone is combined with Galantamine.Approved, Vet Approved
MetipranololGalantamine may increase the bradycardic activities of Metipranolol.Approved
MetixeneThe therapeutic efficacy of Metixene can be decreased when used in combination with Galantamine.Approved
MetoprololGalantamine may increase the bradycardic activities of Metoprolol.Approved, Investigational
MidostaurinThe metabolism of Galantamine can be decreased when combined with Midostaurin.Approved
MifepristoneMifepristone may increase the QTc-prolonging activities of Galantamine.Approved, Investigational
MilnacipranThe metabolism of Galantamine can be decreased when combined with Milnacipran.Approved
MirabegronThe metabolism of Galantamine can be decreased when combined with Mirabegron.Approved
MitotaneThe serum concentration of Galantamine can be decreased when it is combined with Mitotane.Approved
MivacuriumGalantamine may decrease the neuromuscular blocking activities of Mivacurium.Approved
MoxifloxacinGalantamine may increase the QTc-prolonging activities of Moxifloxacin.Approved, Investigational
NadololGalantamine may increase the bradycardic activities of Nadolol.Approved
NCX 1022The risk or severity of adverse effects can be increased when NCX 1022 is combined with Galantamine.Investigational
NebivololGalantamine may increase the bradycardic activities of Nebivolol.Approved, Investigational
NefazodoneThe metabolism of Galantamine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Galantamine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Galantamine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Galantamine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Galantamine can be decreased when combined with Nicardipine.Approved
NicotineThe risk or severity of adverse effects can be increased when Galantamine is combined with Nicotine.Approved
NilotinibGalantamine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
OctreotideOctreotide may increase the bradycardic activities of Galantamine.Approved, Investigational
OfloxacinGalantamine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlaparibThe metabolism of Galantamine can be decreased when combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Oleoyl-estrone is combined with Galantamine.Investigational
OndansetronGalantamine may increase the QTc-prolonging activities of Ondansetron.Approved
OrphenadrineThe therapeutic efficacy of Orphenadrine can be decreased when used in combination with Galantamine.Approved
OsimertinibThe serum concentration of Galantamine can be increased when it is combined with Osimertinib.Approved
OtiloniumThe therapeutic efficacy of Otilonium can be decreased when used in combination with Galantamine.Experimental, Investigational
OxitropiumThe therapeutic efficacy of Oxitropium can be decreased when used in combination with Galantamine.Investigational
OxprenololGalantamine may increase the bradycardic activities of Oxprenolol.Approved
OxybutyninThe therapeutic efficacy of Oxybutynin can be decreased when used in combination with Galantamine.Approved, Investigational
OxyphenoniumThe therapeutic efficacy of Oxyphenonium can be decreased when used in combination with Galantamine.Approved
PalbociclibThe serum concentration of Galantamine can be increased when it is combined with Palbociclib.Approved
PaliperidoneGalantamine may increase the QTc-prolonging activities of Paliperidone.Approved
PancuroniumThe therapeutic efficacy of Pancuronium can be decreased when used in combination with Galantamine.Approved
PanobinostatThe serum concentration of Galantamine can be increased when it is combined with Panobinostat.Approved, Investigational
ParamethasoneThe risk or severity of adverse effects can be increased when Paramethasone is combined with Galantamine.Approved
ParoxetineThe metabolism of Galantamine can be decreased when combined with Paroxetine.Approved, Investigational
PasireotideGalantamine may increase the bradycardic activities of Pasireotide.Approved
PazopanibGalantamine may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Galantamine can be decreased when it is combined with Peginterferon alfa-2b.Approved
PenbutololGalantamine may increase the bradycardic activities of Penbutolol.Approved, Investigational
PentamidineGalantamine may increase the QTc-prolonging activities of Pentamidine.Approved
PentobarbitalThe metabolism of Galantamine can be increased when combined with Pentobarbital.Approved, Vet Approved
PentoliniumThe therapeutic efficacy of Pentolinium can be decreased when used in combination with Galantamine.Approved
PerflutrenGalantamine may increase the QTc-prolonging activities of Perflutren.Approved
PhenglutarimideThe therapeutic efficacy of Phenglutarimide can be decreased when used in combination with Galantamine.Experimental
PhenobarbitalThe metabolism of Galantamine can be increased when combined with Phenobarbital.Approved
PhenytoinThe metabolism of Galantamine can be increased when combined with Phenytoin.Approved, Vet Approved
PilocarpineThe risk or severity of adverse effects can be increased when Galantamine is combined with Pilocarpine.Approved
PimozideGalantamine may increase the QTc-prolonging activities of Pimozide.Approved
PindololGalantamine may increase the bradycardic activities of Pindolol.Approved
PipecuroniumThe therapeutic efficacy of Pipecuronium can be decreased when used in combination with Galantamine.Approved
PirenzepineThe therapeutic efficacy of Pirenzepine can be decreased when used in combination with Galantamine.Approved
Poractant alfaGalantamine may increase the bradycardic activities of Poractant alfa.Approved
PosaconazoleThe metabolism of Galantamine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololGalantamine may increase the bradycardic activities of Practolol.Approved
PrasteroneThe risk or severity of adverse effects can be increased when Prasterone is combined with Galantamine.Approved, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Prasterone sulfate is combined with Galantamine.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Prednicarbate is combined with Galantamine.Approved
PrednisoloneThe risk or severity of adverse effects can be increased when Prednisolone is combined with Galantamine.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Prednisone is combined with Galantamine.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Pregnenolone is combined with Galantamine.Experimental, Investigational
PrimaquineGalantamine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Galantamine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamideGalantamine may increase the QTc-prolonging activities of Procainamide.Approved
ProcyclidineThe therapeutic efficacy of Procyclidine can be decreased when used in combination with Galantamine.Approved
PromazineGalantamine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PropafenoneGalantamine may increase the QTc-prolonging activities of Propafenone.Approved
PropanthelineThe therapeutic efficacy of Propantheline can be decreased when used in combination with Galantamine.Approved
PropiverineThe therapeutic efficacy of Propiverine can be decreased when used in combination with Galantamine.Approved, Investigational
PropranololGalantamine may increase the bradycardic activities of Propranolol.Approved, Investigational
QuetiapineGalantamine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinidineGalantamine may increase the QTc-prolonging activities of Quinidine.Approved
QuinineGalantamine may increase the QTc-prolonging activities of Quinine.Approved
RanolazineThe metabolism of Galantamine can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumGalantamine may decrease the neuromuscular blocking activities of Rapacuronium.Withdrawn
RifabutinThe metabolism of Galantamine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Galantamine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Galantamine can be increased when combined with Rifapentine.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Rimexolone is combined with Galantamine.Approved
RitonavirThe metabolism of Galantamine can be decreased when combined with Ritonavir.Approved, Investigational
RivastigmineGalantamine may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RolapitantThe metabolism of Galantamine can be decreased when combined with Rolapitant.Approved
RopiniroleThe metabolism of Galantamine can be decreased when combined with Ropinirole.Approved, Investigational
RuxolitinibRuxolitinib may increase the bradycardic activities of Galantamine.Approved
SaquinavirThe metabolism of Galantamine can be decreased when combined with Saquinavir.Approved, Investigational
ScopolamineThe therapeutic efficacy of Scopolamine can be decreased when used in combination with Galantamine.Approved
Scopolamine butylbromideThe therapeutic efficacy of Scopolamine butylbromide can be decreased when used in combination with Galantamine.Approved, Vet Approved
SertralineThe metabolism of Galantamine can be decreased when combined with Sertraline.Approved
SildenafilThe metabolism of Galantamine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Galantamine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Galantamine can be increased when it is combined with Simeprevir.Approved
SolifenacinThe therapeutic efficacy of Solifenacin can be decreased when used in combination with Galantamine.Approved
SotalolGalantamine may increase the QTc-prolonging activities of Sotalol.Approved
St. John's WortThe serum concentration of Galantamine can be decreased when it is combined with St. John's Wort.Investigational, Nutraceutical
StiripentolThe serum concentration of Galantamine can be increased when it is combined with Stiripentol.Approved
SuccinylcholineThe serum concentration of Succinylcholine can be increased when it is combined with Galantamine.Approved
SufentanilGalantamine may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulfisoxazoleGalantamine may increase the QTc-prolonging activities of Sulfisoxazole.Approved, Vet Approved
TalinololGalantamine may increase the bradycardic activities of Talinolol.Investigational
TelaprevirThe metabolism of Galantamine can be decreased when combined with Telaprevir.Approved, Withdrawn
TelavancinGalantamine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinThe metabolism of Galantamine can be decreased when combined with Telithromycin.Approved
TerbinafineThe metabolism of Galantamine can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TertatololGalantamine may increase the bradycardic activities of Tertatolol.Experimental
TetrabenazineGalantamine may increase the QTc-prolonging activities of Tetrabenazine.Approved
ThioridazineGalantamine may increase the QTc-prolonging activities of Thioridazine.Approved, Withdrawn
TiclopidineThe metabolism of Galantamine can be decreased when combined with Ticlopidine.Approved
TimololGalantamine may increase the bradycardic activities of Timolol.Approved
TiotropiumThe therapeutic efficacy of Tiotropium can be decreased when used in combination with Galantamine.Approved
TipranavirThe metabolism of Galantamine can be decreased when combined with Tipranavir.Approved, Investigational
TixocortolThe risk or severity of adverse effects can be increased when Tixocortol is combined with Galantamine.Approved
TizanidineGalantamine may increase the bradycardic activities of Tizanidine.Approved
TocilizumabThe serum concentration of Galantamine can be decreased when it is combined with Tocilizumab.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Galantamine.Approved, Investigational
TolterodineThe therapeutic efficacy of Tolterodine can be decreased when used in combination with Galantamine.Approved, Investigational
ToremifeneGalantamine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TranylcypromineThe metabolism of Galantamine can be decreased when combined with Tranylcypromine.Approved
TriamcinoloneThe risk or severity of adverse effects can be increased when Triamcinolone is combined with Galantamine.Approved, Vet Approved
TrihexyphenidylThe therapeutic efficacy of Trihexyphenidyl can be decreased when used in combination with Galantamine.Approved
TrimethaphanThe therapeutic efficacy of Trimethaphan can be decreased when used in combination with Galantamine.Approved, Investigational
TropatepineThe therapeutic efficacy of Tropatepine can be decreased when used in combination with Galantamine.Experimental
TropicamideThe therapeutic efficacy of Tropicamide can be decreased when used in combination with Galantamine.Approved
TrospiumThe therapeutic efficacy of Trospium can be decreased when used in combination with Galantamine.Approved
TubocurarineThe therapeutic efficacy of Tubocurarine can be decreased when used in combination with Galantamine.Approved
VandetanibGalantamine may increase the QTc-prolonging activities of Vandetanib.Approved
VareniclineThe risk or severity of adverse effects can be increased when Galantamine is combined with Varenicline.Approved, Investigational
VecuroniumThe therapeutic efficacy of Vecuronium can be decreased when used in combination with Galantamine.Approved
VemurafenibGalantamine may increase the QTc-prolonging activities of Vemurafenib.Approved
VenlafaxineThe metabolism of Galantamine can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Galantamine can be decreased when combined with Verapamil.Approved
VoriconazoleThe metabolism of Galantamine can be decreased when combined with Voriconazole.Approved, Investigational
ZimelidineThe metabolism of Galantamine can be decreased when combined with Zimelidine.Withdrawn
ZiprasidoneGalantamine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZuclopenthixolGalantamine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food Interactions
  • Take with food.

References

Synthesis Reference

Vijaya Bolugoddu, Sanjay Shukla, Mukunda Jambula, Rajeshwar Sagyam, Ramchandra Pingili, Ananda Thirunavakarasu, "Preparation of (-)-galantamine hydrobromide." U.S. Patent US20060009640, issued January 12, 2006.

US20060009640
General References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. [PubMed:10606746]
  3. Woodruff-Pak DS, Vogel RW 3rd, Wenk GL: Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2089-94. Epub 2001 Feb 6. [PubMed:11172080]
  4. Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. [PubMed:16437532]
  5. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  6. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
External Links
Human Metabolome Database
HMDB14812
KEGG Drug
D04292
KEGG Compound
C08526
PubChem Compound
9651
PubChem Substance
46505659
ChemSpider
9272
BindingDB
10404
ChEBI
42944
ChEMBL
CHEMBL659
Therapeutic Targets Database
DAP000559
PharmGKB
PA449726
HET
GNT
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Galantamine
ATC Codes
N06DA04 — Galantamine
AHFS Codes
  • 12:04.00 — Parasympathomemetic (Cholinergic) Agents
PDB Entries
1dx6 / 1qti / 1w6r / 1w76 / 2ph9 / 4ey6
FDA label
Download (278 KB)
MSDS
Download (28.4 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1Active Not RecruitingTreatmentInsulin Sensitivity / Oxidative Stress1
1CompletedNot AvailableAlzheimer's Disease (AD)1
1CompletedNot AvailableHealthy Volunteers2
1CompletedScreeningMemory1
1CompletedTreatmentAlzheimer's Disease (AD)1
1CompletedTreatmentFasting1
1CompletedTreatmentFed1
1CompletedTreatmentPharmacokinetics1
1CompletedTreatmentSmoking / Tobacco Withdrawal1
1RecruitingBasic SciencePostural Tachycardia Syndrome1
1, 2RecruitingTreatmentBMI >30 kg/m21
2Active Not RecruitingPreventionSchizophrenic Disorders1
2CompletedTreatmentDependence, Cocaine1
2CompletedTreatmentFrontotemporal Dementia / Pick Complex1
2CompletedTreatmentNicotine Addiction1
2CompletedTreatmentSchizophrenic Disorders1
2RecruitingTreatmentCognitive Impairments / Strokes1
2RecruitingTreatmentTobacco Use Disorders1
2TerminatedTreatmentPosttraumatic Stress Disorders / Traumatic Brain Injury (TBI)1
2TerminatedTreatmentSchizoaffective Disorders / Schizophrenic Disorders1
2, 3CompletedTreatmentSchizophrenic Disorders1
2, 3RecruitingNot AvailableDementia, Vascular / Mild Cognitive Disorder (Vascular) / Mild Cognitive Impairment (Vascular)1
3CompletedTreatmentAlzheimer's Disease (AD)6
3CompletedTreatmentAlzheimer's Disease (AD) / Brain Diseases / Dementias / Psychiatric Disorder NOS1
3CompletedTreatmentAlzheimer's Disease (AD) / Dementia, Vascular1
3CompletedTreatmentAlzheimer's Disease (AD) / Dementias9
3CompletedTreatmentAutism, Early Infantile1
3CompletedTreatmentBrain Diseases / Cognition Disorder / Nervous System Diseases / Psychiatric Disorder NOS1
3CompletedTreatmentDementia, Vascular1
3CompletedTreatmentDepression, Bipolar / Major Depressive Disorder (MDD) / Schizoaffective Disorders1
3CompletedTreatmentDiffuse Lewy Body Disease1
3TerminatedTreatmentAlzheimer's Disease (AD)1
3TerminatedTreatmentAnxiety Disorders / Dementias / Depressive State / Psychosomatic Disorders / Schizophrenic Disorders1
4CompletedNot AvailableAlzheimer's Disease (AD)2
4CompletedNot AvailableAlzheimer's Disease (AD) / Dementia, Vascular / Dementias1
4CompletedNot AvailableAlzheimer's Disease (AD) / Dementias / Galantamine1
4CompletedTreatmentAbdominal Obesity Metabolic Syndrome1
4CompletedTreatmentAlzheimer's Disease (AD)4
4CompletedTreatmentBipolar Disorder (BD)1
4CompletedTreatmentCerebrovascular Accidents1
4CompletedTreatmentDementias1
4CompletedTreatmentSchizoaffective Disorders / Schizophrenic Disorders2
4CompletedTreatmentTardive Dyskinesia1
4TerminatedBasic ScienceAlzheimer's Disease (AD)1
4TerminatedTreatmentAlzheimer's Disease (AD)1
4TerminatedTreatmentDepressive State1
4TerminatedTreatmentGilles de la Tourette's Syndrome / Motor Tic Disorder / Vocal Tic Disorder1
4TerminatedTreatmentPsychotic Disorder NOS / Schizophrenic Disorders1
4Unknown StatusTreatmentAlzheimer's Disease (AD)1
4Unknown StatusTreatmentHead Trauma,Closed / Post-Traumatic Headaches / Retention Disorders, Cognitive1
Not AvailableCompletedNot AvailableBiomarkers, Pharmacological1
Not AvailableCompletedNot AvailableDiffuse Lewy Body Disease1
Not AvailableCompletedBasic ScienceBasic Science Study of the Mechanisms of Attentional Enhancement by Compounds Acting on the Nicotinic Receptor1
Not AvailableCompletedTreatmentAddictions1
Not AvailableCompletedTreatmentAphasia / Strokes1
Not AvailableCompletedTreatmentChronic Schizophrenia1
Not AvailableCompletedTreatmentCocaine Abuse1
Not AvailableCompletedTreatmentDementias1
Not AvailableCompletedTreatmentNicotine Dependence1
Not AvailableTerminatedTreatmentAlzheimer's Disease (AD) / Dementias1
Not AvailableUnknown StatusPreventionParkinson's Disease (PD)1

Pharmacoeconomics

Manufacturers
  • Barr laboratories inc
  • Impax laboratories inc
  • Watson laboratories inc
  • Ortho mcneil janssen pharmaceuticals inc
  • Roxane laboratories inc
  • Ortho mcneil janssen pharmaceutical inc
  • Actavis elizabeth llc
  • Beijing yabao biopharmaceutical co ltd
  • Dr reddys laboratories ltd
  • Mylan pharmaceuticals inc
  • Sandoz inc
  • Teva pharmaceuticals usa
Packagers
Dosage forms
FormRouteStrength
TabletOral12 mg/1
TabletOral4 mg/1
TabletOral8 mg/1
Capsule, extended releaseOral16 mg/1
Capsule, extended releaseOral24 mg/1
Capsule, extended releaseOral8 mg/1
Tablet, film coatedOral12 mg/1
Tablet, film coatedOral4 mg/1
Tablet, film coatedOral8 mg/1
Capsule, extended releaseOral16 mg
Capsule, extended releaseOral24 mg
Capsule, extended releaseOral8 mg
SolutionOral4 mg/mL
TabletOral12 mg
TabletOral4 mg
TabletOral8 mg
Prices
Unit descriptionCostUnit
Galantamine Hydrobromide 30 16 mg 24 Hour Capsule Bottle198.58USD bottle
Galantamine Hydrobromide 30 8 mg 24 Hour Capsule Bottle198.58USD bottle
Razadyne 12 mg tablet8.3USD tablet
Razadyne 4 mg tablet5.36USD tablet
Razadyne 8 mg tablet3.66USD tablet
Galantamine hbr 12 mg tablet3.18USD tablet
Galantamine hbr 4 mg tablet3.18USD tablet
Galantamine hbr 8 mg tablet3.18USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
CA2358062No2006-12-192019-12-20Canada
CA2310926No2001-11-202017-06-06Canada
US6358527No1997-06-062017-06-06Us
US6099863No1997-06-062017-06-06Us
US7160559No1999-12-202019-12-20Us

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)269-270 °C (HBr salt)Not Available
water solubility10 mg/mL (HBr salt)Not Available
logP1.8Not Available
Predicted Properties
PropertyValueSource
Water Solubility1.7 mg/mLALOGPS
logP1.39ALOGPS
logP1.16ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)14.81ChemAxon
pKa (Strongest Basic)8.91ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area41.93 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity82.3 m3·mol-1ChemAxon
Polarizability31.4 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9959
Caco-2 permeable+0.8259
P-glycoprotein substrateSubstrate0.8976
P-glycoprotein inhibitor IInhibitor0.6069
P-glycoprotein inhibitor IINon-inhibitor0.9443
Renal organic cation transporterInhibitor0.5728
CYP450 2C9 substrateNon-substrate0.8072
CYP450 2D6 substrateSubstrate0.8919
CYP450 3A4 substrateSubstrate0.7408
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.5414
CYP450 2C19 inhibitorNon-inhibitor0.8301
CYP450 3A4 inhibitorNon-inhibitor0.8832
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9439
Ames testNon AMES toxic0.7995
CarcinogenicityNon-carcinogens0.9055
BiodegradationNot ready biodegradable1.0
Rat acute toxicity2.7790 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8023
hERG inhibition (predictor II)Non-inhibitor0.7424
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Mass Spectrum (Electron Ionization)MSsplash10-000l-5980000000-928ad889466b6a2b3827
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-000i-0390000000-f4f443a7f842d92dec39

Taxonomy

Description
This compound belongs to the class of organic compounds known as galanthamine-type amaryllidaceae alkaloids. These are amaryllidaceae alkaloids with a structure characterized a tetracyclic skeleton with two ortho aromatic protons in ring A.
Kingdom
Organic compounds
Super Class
Alkaloids and derivatives
Class
Amaryllidaceae alkaloids
Sub Class
Galanthamine-type amaryllidaceae alkaloids
Direct Parent
Galanthamine-type amaryllidaceae alkaloids
Alternative Parents
Benzazepines / Coumarans / Anisoles / Azepines / Aralkylamines / Alkyl aryl ethers / Trialkylamines / Secondary alcohols / Oxacyclic compounds / Azacyclic compounds
show 2 more
Substituents
Galanthamine-type amaryllidaceae alkaloid / Benzazepine / Coumaran / Anisole / Alkyl aryl ether / Azepine / Aralkylamine / Benzenoid / Secondary alcohol / Tertiary amine
show 14 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
tertiary amino compound, organic heterotetracyclic compound, benzazepine alkaloid, benzazepine alkaloid fundamental parent (CHEBI:42944) / Isoquinoline alkaloids (C08526)

Targets

Details
1. Acetylcholinesterase
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Inhibitor
General Function
Serine hydrolase activity
Specific Function
Terminates signal transduction at the neuromuscular junction by rapid hydrolysis of the acetylcholine released into the synaptic cleft. Role in neuronal apoptosis.
Gene Name
ACHE
Uniprot ID
P22303
Uniprot Name
Acetylcholinesterase
Molecular Weight
67795.525 Da
References
  1. Tonkopii VD, Prozorovskii VB, Suslova IM: [Interaction of reversible inhibitors with the catalytic centers and allosteric sites of cholinesterases]. Biull Eksp Biol Med. 1976 Aug;82(8):947-50. [PubMed:1026294]
  2. Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. [PubMed:10606746]
  3. Guillou C, Mary A, Renko DZ, Gras E, Thal C: Potent acetylcholinesterase inhibitors: design, synthesis and structure-activity relationships of alkylene linked bis-galanthamine and galanthamine-galanthaminium salts. Bioorg Med Chem Lett. 2000 Apr 3;10(7):637-9. [PubMed:10762042]
  4. Blesa R: Galantamine: therapeutic effects beyond cognition. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:28-34. [PubMed:10971049]
  5. Stahl SM: The new cholinesterase inhibitors for Alzheimer's disease, Part 1: their similarities are different. J Clin Psychiatry. 2000 Oct;61(10):710-1. [PubMed:11078030]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  8. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  9. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  10. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  11. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  12. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
  13. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [PubMed:10592235]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA1
Uniprot ID
P02708
Uniprot Name
Acetylcholine receptor subunit alpha
Molecular Weight
54545.235 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNB1
Uniprot ID
P11230
Uniprot Name
Acetylcholine receptor subunit beta
Molecular Weight
56697.9 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Acetylcholine-activated cation-selective channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRND
Uniprot ID
Q07001
Uniprot Name
Acetylcholine receptor subunit delta
Molecular Weight
58894.55 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNG
Uniprot ID
P07510
Uniprot Name
Acetylcholine receptor subunit gamma
Molecular Weight
57882.8 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Cation transmembrane transporter activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNE
Uniprot ID
Q04844
Uniprot Name
Acetylcholine receptor subunit epsilon
Molecular Weight
54696.54 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA2
Uniprot ID
Q15822
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-2
Molecular Weight
59764.82 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA3
Uniprot ID
P32297
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-3
Molecular Weight
57479.54 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNA4
Uniprot ID
P43681
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-4
Molecular Weight
69956.47 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA5
Uniprot ID
P30532
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-5
Molecular Weight
53053.965 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Acetylcholine-activated cation-selective channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNA6
Uniprot ID
Q15825
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-6
Molecular Weight
56897.745 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Toxic substance binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane. The cha...
Gene Name
CHRNA7
Uniprot ID
P36544
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-7
Molecular Weight
56448.925 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Calcium channel activity
Specific Function
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding induces a conformation change that leads to the opening of an ion-conducting channel across the plasm...
Gene Name
CHRNA9
Uniprot ID
Q9UGM1
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-9
Molecular Weight
54806.63 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Receptor binding
Specific Function
Ionotropic receptor with a probable role in the modulation of auditory stimuli. Agonist binding may induce an extensive change in conformation that affects all subunits and leads to opening of an i...
Gene Name
CHRNA10
Uniprot ID
Q9GZZ6
Uniprot Name
Neuronal acetylcholine receptor subunit alpha-10
Molecular Weight
49704.295 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane permeabl...
Gene Name
CHRNB2
Uniprot ID
P17787
Uniprot Name
Neuronal acetylcholine receptor subunit beta-2
Molecular Weight
57018.575 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Drug binding
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNB3
Uniprot ID
Q05901
Uniprot Name
Neuronal acetylcholine receptor subunit beta-3
Molecular Weight
52728.215 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Allosteric modulator
General Function
Ligand-gated ion channel activity
Specific Function
After binding acetylcholine, the AChR responds by an extensive change in conformation that affects all subunits and leads to opening of an ion-conducting channel across the plasma membrane.
Gene Name
CHRNB4
Uniprot ID
P30926
Uniprot Name
Neuronal acetylcholine receptor subunit beta-4
Molecular Weight
56378.985 Da
References
  1. Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. [PubMed:11129124]
  2. Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. [PubMed:12177686]
  3. Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. [PubMed:12137632]
  4. Lilienfeld S, Parys W: Galantamine: additional benefits to patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2000 Sep;11 Suppl 1:19-27. [PubMed:10971048]
  5. Woodruff-Pak DS, Lander C, Geerts H: Nicotinic cholinergic modulation: galantamine as a prototype. CNS Drug Rev. 2002 Winter;8(4):405-26. [PubMed:12481195]
  6. Hansen RA, Gartlehner G, Kaufer DJ, Lohr KN, Carey T: Drug Class Review: Alzheimer's Drugs: Final Report [Internet] . [PubMed:20480924]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Identical protein binding
Specific Function
Esterase with broad substrate specificity. Contributes to the inactivation of the neurotransmitter acetylcholine. Can degrade neurotoxic organophosphate esters.
Gene Name
BCHE
Uniprot ID
P06276
Uniprot Name
Cholinesterase
Molecular Weight
68417.575 Da
References
  1. Svoboda Z, Kvetina J, Kunesova G, Herink J, Bajgar J, Bartosova L, Zivny P, Palicka V: Effect of galantamine on acetylcholinesterase and butyrylcholinesterase activities in the presence of L-carnitine in rat selected brain and peripheral tissues. Neuro Endocrinol Lett. 2006 Dec;27 Suppl 2:183-6. [PubMed:17159811]
  2. Giacobini E: Selective inhibitors of butyrylcholinesterase: a valid alternative for therapy of Alzheimer's disease? Drugs Aging. 2001;18(12):891-8. [PubMed:11888344]
  3. Wilkinson DG: Galantamine: a new treatment for Alzheimer's disease. Expert Rev Neurother. 2001 Nov;1(2):153-9. doi: 10.1586/14737175.1.2.153. [PubMed:19811027]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on June 13, 2005 07:24 / Updated on November 13, 2017 21:49